---
figid: PMC9520173__10.1177_11795549221126252-fig1
figtitle: Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
organisms:
- NA
pmcid: PMC9520173
filename: 10.1177_11795549221126252-fig1.jpg
figlink: /pmc/articles/PMC9520173/figure/fig1-11795549221126252/
number: F1
caption: 'FGF/FGFR signaling pathway. AKT indicates Ak strain transforming; FGFR,
  fibroblast growth factor receptor; MAPK, mitogen-activated protein kinase; PI3K,
  phosphoinositide 3-kinase.Source: Adapted from BioRender.com.License permits BioRender
  content to be sublicensed for use in Clinical Medicine Insights: Oncology.'
papertitle: Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma.
reftext: David J Benjamin, et al. Clin Med Insights Oncol. 2022;16:11795549221126252.
year: '2022'
doi: 10.1177/11795549221126252
journal_title: Clinical Medicine Insights. Oncology
journal_nlm_ta: Clin Med Insights Oncol
publisher_name: SAGE Publications
keywords: Urothelial carcinoma | bladder cancer | FGFR | erdafitinib | checkpoint
  inhibitor | immunotherapy
automl_pathway: 0.9386352
figid_alias: PMC9520173__F1
figtype: Figure
organisms_ner:
- Drosophila melanogaster
redirect_from: /figures/PMC9520173__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9520173__10.1177_11795549221126252-fig1.html
  '@type': Dataset
  description: 'FGF/FGFR signaling pathway. AKT indicates Ak strain transforming;
    FGFR, fibroblast growth factor receptor; MAPK, mitogen-activated protein kinase;
    PI3K, phosphoinositide 3-kinase.Source: Adapted from BioRender.com.License permits
    BioRender content to be sublicensed for use in Clinical Medicine Insights: Oncology.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Raf
  - MKP-4
  - p38b
  - rl
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - sl
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
---
